The path from the incretin effect in the 1960s to triple agonists in the 2020s is one of the fastest stories in pharmacology.
| Year | Milestone |
|---|---|
| 1960-70s | Incretin effect discovered: insulin response higher for oral glucose |
| 1980s | GLP-1 identified as the active hormone |
| 2005 | Exenatide (Byetta) — from Gila monster saliva, first GLP-1 drug |
| 2010 | Liraglutide (Victoza/Saxenda) — daily |
| 2017 | Semaglutide (Ozempic) — weekly |
| 2022 | Tirzepatide (Mounjaro) — dual GIP+GLP-1 |
| 2020s | Retatrutide — triple GIP+GLP-1+GCG |
Long half-lives (acylation — an 'anchor' to albumin) turned daily injections weekly; multi-agonism widened targets. Our class pages: mechanics (RU) · encyclopedia.
Exenatide — from a compound in Gila monster saliva.
An acylated side chain binds albumin — half-life ~165 h.
5/5 from 19 published reviews with photos (as of 12 Nov 2026). Published and dated — not chat screenshots.
«Really good support & product, best seller here in Vietnam! Works like a charm ❤️»
«I feel the effects already. I'm very glad that I found your product.»
«Thank you so much for your support in this. I'm excited to get back going.»
«Everything was fine. Minimal side effects, results are looking great.»
«Everything went well. Thank you! 🤍»